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Radiological imaging techniques, including magnetic resonance imaging (MRI) and
positron emission tomography (PET), are the standard-of-care non-invasive
diagnostic approaches widely applied in neuro-oncology. Unfortunately,
accurate interpretation of radiological imaging data is constantly challenged by
the indistinguishable radiological image features shared by different pathological
changes associated with tumor progression and/or various therapeutic
interventions. In recent years, machine learning (ML)-based artiﬁcial intelligence
(AI) technology has been widely applied in medical image processing and
bioinformatics due to its advantages in implicit image feature extraction and
integrative data analysis. Despite its recent rapid development, ML technology
still faces many hurdles for its broader applications in neuro-oncological radiomic
analysis, such as lack of large accessible standardized real patient radiomic brain
tumor data of all kinds and reliable predictions on tumor response upon various
treatments. Therefore, understanding ML-based AI technologies is critically
important to help us address the skyrocketing demands of neuro-oncology
clinical deployments. Here, we provide an overview on the latest advancements
in ML techniques for brain tumor radiomic analysis, emphasizing proprietary and
public dataset preparation and state-of-the-art ML models for brain tumor
diagnosis, classiﬁcations (e.g., primary and secondary tumors), discriminations
between treatment effects (pseudoprogression, radiation necrosis) and true
progression, survival prediction, inﬂammation, and identiﬁcation of brain tumor
biomarkers. We also compare the key features of ML models in the realm of
neuroradiology with ML models employed in other medical imaging ﬁelds and
discuss open research challenges and directions for future work in this nascent
precision medicine area.
KEYWORDS

artiﬁcial intelligence, machine learning, brain tumor, immunotherapy, radiomics,
tumor classiﬁcation, survival prediction, radiogenomics
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Introduction

learning infers the inherent structure from the input data
without labels/annotations (10). In reinforcement learning,
intelligent agents learn to take actions in an environment in
order to maximize the notion of cumulative reward (11).
Currently, most AI techniques applied in brain tumor
radiomic studies belong to the supervised ML, for both
classiﬁcations and segmentations. Unsupervised ML is mainly
employed for image segmentations while reinforcement learning
has not been explored in this area. Therefore, in this paper, we
mainly focus on the supervised ML techniques for most GBM
radiomic analyses. Thanks to the rapid development of radiology
and computational hardware, researchers can now take
advantage of many radiological data to train various ML
models, such as decision trees (DTs), logistic regression,
artiﬁcial neural networks (ANNs), support vector machines
(SVMs), and k-nearest neighbors (k-NN) for brain tumor
radiomic analysis. The different techniques applied in AI
(mainly ML algorithms) are the technical core for the analysis
of large amounts of multidimensional radiologic and clinical
data (12), which directly determine the quality of radiomic
analysis results.
In the past decade, ML has been widely exploited in many
data-driven applications, e.g., imaging and computer vision (13),
bioinformatics (14), online advertising (15), and natural
language processing (16). The dataﬂow of a general supervised
ML-based GBM radiomic analysis can be divided into four steps
as shown Figure 1A: 1) Data Acquisition. MRIs are performed on
patients with a brain tumor. These raw MRI data are further
preprocessed (e.g., data cleaning, co-registration, bias correction,
normalization), and then they are labeled/annotated by
radiologists to deﬁne the regions for the ML training and
validation process. The labeled/annotated imaging data are
deposited into customized/private datasets that are owned and
maintained by medical research institutions. Some imaging data
are also uploaded into public datasets for the purpose of open
access to all researchers. AI-assisted radiomic analysis can
acquire imaging data from both types of datasets. It is of note,
however, that private datasets usually contain a fairly large
amount of raw data, hundreds of samples for each institution
if applicable, whereas public datasets usually contain limited
amount of less well-labeled/annotated, non-standardized
imaging data (17); 2) Data Augmentation and Preprocessing
for ML Models. The acquired data and its labels/annotations are
usually ﬁrst subject to augmentation, in which image data are
processed in pair-wise format (i.e., each pair contains a data
sample and the corresponding labels/annotations) to increase
the sample variety, hence improving the generality of the data.
Multiple approaches are utilized in augmentation, such as
geometric transformation, color augmentation, and synthesis
of similar-appearing imaging data. Then, the augmented
imaging data can be preprocessed (e.g., through feature
extraction) to simplify and/or to improve the effectiveness and

Glioblastoma (GBM, WHO grade 4 glioma, IDH-wildtype)
is the most aggressive primary brain tumor in adults with a
dismal median overall survival (OS) of only 12 to 18 months and
a 5-year OS rate of 6.8% (1, 2). Approximately 13,000 GBM cases
are diagnosed in the United States each year, with an incidence
rate of 3.2 per 100,000 members of the population (3, 4). Despite
standard-of-care therapy including aggressive surgical resection
followed by radiation therapy and chemotherapy, more than
90% of glioblastomas recur (4). To date, magnetic resonance
imaging (MRI) remains the standard approach in the diagnosis,
prognosis, and therapeutic monitoring of GBM patients because
it is non-invasive, accessible, and cost efﬁcient. However,
interpretation of radiological imaging data can be subjective,
challenging, and time-consuming, mainly because histologic
ﬁndings are often radiologically occult. For example, therapyinduced treatment effect (i.e., pseudoprogression (PsP) or
radiation necrosis) and true tumor progression manifest with
identical MRI appearances, and differentiation between these
entities remains an unsolved conundrum in current neuroradio-oncology, particularly with novel therapies such as
immune checkpoint inhibitors (5).
Radiomics (6, 7) in neuro-oncology seeks to improve the
understanding of the biology and effects of treatment on the
imaging appearance of brain tumors. Radiomics can promote
precision medicine by extracting quantitative features from
clinical imaging arrays and using methods from the ﬁeld of
artiﬁcial intelligence (AI) to make the radiological diagnosis
more objective, accurate, and automatic. Rather than designing
hard-coded step-by-step algorithms based on prior knowledge in
biology or medicine, or design speciﬁc “learning” approaches to
mimic human cognitive functions, machine learning (ML) as a
subﬁeld of AI can create a computational model and train it with
a number of datasets to statistically solve problems without
being explicitly programmed (8). Generally, ML includes
supervised learning, unsupervised learning, and reinforcement
learning. Supervised learning trains an ML model to predict a
target variable from a set of predictive variables (i.e., data
samples) with the help of labels/annotations (i.e., ground truth
of the target variables) and the loss function, also known as cost
function, which is a computational difference between predicted
target variable values and the label/annotation values (9). It
should be noted that, although labeling and annotation share the
same meaning in ML, they slightly differ in neuro-oncology
radiomic analysis. In the context of this manuscript, labeling is
related with classiﬁcation problems (e.g., the ground truth of
tissue is histological, including different classes of brain tumors,
treatment effect versus tumor growth, and others) whereas
annotation refers to segmentation problems (partitioning an
image into multiple regions/objects, such as enhancing tumor,
necrosis, and unenhancing tumor and edema). Unsupervised
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FIGURE 1

AI/ML in GBM radiomic analysis: (A) Overall workﬂow of AI-assisted GBM analysis: 1) Data Acquisition. Raw radiological image data are acquired
by MRI scanning of GBM patients. Images are collected into public or private data sets. Before analysis, images are preprocessed (e.g., data
cleaning, co-registration, normalization) and standardized (e.g., format, resolutions, voxel sizes). Then, radiologists annotate the images, colorcoding different parts of the tumor habitat. 2) Data Augmentation and Preprocessing for ML Models. Imaging dataset and its annotations from
step 1 are further “augmented” via geometric transformations, photometric transformation, and/or synthetic data (e.g., GAN) to improve the data
generalizability, followed by the optional preprocessing for ML modeling, a process that includes feature extraction to ﬁlter out “useless” data
and extract explicit features (e.g., biological and/or geometry) in the images. 3) ML modeling and training. Augmented and preprocessed data
are fed into various ML models (e.g., SVM, RF, CNN) for GBM radiomic analysis training and validation. Advanced techniques such as transfer
learning and multimodal data fusion (e.g., clinical and genomic data) can be employed to improve the training accuracy as well as generality. 4)
AI-Assisted Clinical Diagnosis/Deployment. Predictions from the ML models for various medical demands, such as differential diagnosis and
survival estimation. (B) Current major challenges (left panel: 1, 2, 3) and perspectives for corresponding solutions (right panel: 1*, 2*, 3*) in AI/
ML-assisted GBM radiomic analysis: 1→1* Current GBM radiological image datasets are limited in low numbers, insufﬁcient annotations, and
poor organization. Enrichment and standardization of current GBM radiological datasets are urgently needed, while incorporation of clinical
and/or genomic data (red circle) can further enhance the performance of ML prediction models; 2→2* develop more comprehensive ML
models to further improve the prediction accuracy and address the relatively low generalizability of current models; 3→3* further strengthen
collaborations among clinicians, biomedical researchers, and computer scientists to overcome the lack of efﬁcient communications between
these parties for the highly multidisciplinary research.

studies. Recently, ANN, especially convolutional neural network
(CNN)-based deep learning (DL), is gaining popularity because
of its improved scalability and the capability of exploiting deep
layers to extract implicit local and global features in neurooncology images. They can achieve state-of-the-art performance
in object detection and tracking (27, 28), image classiﬁcation,
and semantic segmentation (25, 29–32). In ML, each “neuron” is
referring to a computational unit in the ANN rather than a
biological neural. With more complicated ML models and
structures (e.g., more neuron network layers, more neurons in
each layer) and a larger number of parameters introduced into
the neural network, the training process intends to extract more
features but may suffer extensive computational performance
degradation and overﬁtting of the trained model. Current stateof-the-art ML models can achieve an accuracy as high as 0.97
(i.e., 97%) in brain tumor radiomic analysis (33). However, these
results are based on a limited number of datasets and from
retrospective studies, which may still not be generalizable for
patients from different geographic locations. Therefore, current
clinical brain tumor radiomic analysis cannot entirely rely on the
ML-based techniques and still needs manual veriﬁcation. In

efﬁciency of the subsequent ML training process (18); 3) ML
Model Training and Validation: The augmented and
preprocessed data are subsequently fed to ML models to train
the model parameters in order to minimize the “cost function,”
while the implicit data feature will be extracted statistically. The
ML models are also validated during the training process to
prevent overﬁtting, which is when the trained ANN model only
predicts accurately to the training dataset but loses the
generalizability to new samples (19); 4) AI-Assisted Clinical
Diagnosis/Deployment. Once the trained models meet the
accuracy requirement, they can be deployed to the application
to perform predictions such as classiﬁcation and segmentation.
As aforementioned, no biologic hypothesis or knowledge is
required to build an ML model. However, inclusion of this
information and/or other forms of data (e.g., clinical data,
genomic data) may help with the overall ML model
performance by reducing the data size or improving the data
quality during the preprocessing step.
Traditional ML methods such as SVMs (20–22) and random
forests (RFs) (23–26), an ensemble combination of decision
trees, are commonly used for pattern classiﬁcation in tumor
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challenges regarding AI/ML applications in GBM radiomic
analysis, including 1) the most challenging issues affecting the
generalizability and accuracy of AI-assisted radiomic GBM
analysis; 2) promising strategies to enhance performance of AI
models in GBM radiomic analysis; 3) outlook on the
collaborative teamwork between computer scientists,
engineers, physicians, and biomedical researchers. By
elaborating current research developments and challenges in
the state-of-the-art ML-assisted GBM analysis, we hope to
inspire researchers from different ﬁelds for the development of
the next generation of AI-assisted radiomic tools that can
signiﬁcantly improve early detection, treatment efﬁcacy, and
life quality of patients with GBM.

summary, existing ML techniques can only partially fulﬁll the
need for automatic detection and analysis of GBM
characteristics for both clinical and preclinical studies (34–37).
In addition to the ML techniques, the quality of radiologic
images that are used for ML training dramatically affects the
outcomes of radiomic analysis. Radiological images can be
acquired from different imaging modalities, such as MRI,
computed tomography (CT), and positron emission
tomography (PET). Among these, MRI image data are
currently employed as an essential data type in radiomic
neuro-oncology applications because 1) they provide exquisite
detail of brain, spinal cord, and vascular anatomy through
excellent tissue contrast in any imaging plane; 2) different MRI
sequences are able to capture key components of tumor biology
with high sensitivity, such as blood–brain barrier breakdown,
necrosis, edema, non-enhancing tumor inﬁltration, blood ﬂow,
and cellular density, and can distinguish tumoral subcompartments that are likely to reﬂect local cellular
phenotypes and genotypes; and 3) they can non-invasively and
non-destructively interrogate tumors repeatedly to assess
response to treatment and thus they can be integrated into
therapeutic strategies. Understanding these image-based features
is critical as they not only represent a key data resource in
radiomic analysis (6) but also help improve the accuracy and
other performance criteria of ML models.
In this review, we provide an overview of the latest
advancements and in-depth discussions on the most urgent
and challenging questions of AI-assisted GBM radiomic
analysis. Given the exponential increase of AI-based radiomic
studies led by researchers from various backgrounds, such as
oncology, radiology, computer science, and engineering, our
review article brieﬂy explains the key concepts of ML
techniques instead of delving into the technical details. This
article is structured with emphases on the deployments of
various ML techniques in meeting speciﬁc GBM radiomic
clinical needs, e.g., differentiating GBM from other brain
tumors or non-tumors, predicting overall survival (OS), and
correlating with other biomarkers. First, as ML technology in
radiomics is radiological imaging data-driven, we start with the
discussion on imaging data preparations that are commonly
employed in current GBM radiomic analyses. We brieﬂy
introduce the acquisition pipeline for private or customized
imaging datasets and summarize public radiologic datasets
that are currently available for researchers to train their ML
models for various applications. We also describe general
methods for data augmentation and preprocessing for ML
models, which are critical for training, validation, and testing
of ML algorithms. Next, we overview the ML techniques that
have been employed in radiomic analysis for GBM diagnosis and
treatment. Advantages and limitations of existing ML models
including both algorithms and architectures are discussed in the
context of various GBM-associated medical applications. Finally,
we bring up our perspectives on the strategies for overcoming

Frontiers in Oncology

Radiomic data preparation
As ML is an intensive data-driven algorithm/process, the
quality of the training data can signiﬁcantly inﬂuence the
trainable parameters in ML models, hence affecting the accuracy
and generalizability of the network outcomes (38). Thus, it is
essential to review the key components of data preparation in
ML-based GBM radiomic analysis, including radiological imaging
data resources, the image acquisition pipeline, imaging datasets
(private/customized datasets vs. publicly accessible datasets), data
augmentation, and preprocessing techniques for the subsequent ML
model training.

Radiomic image resources
MRI is the most frequently used radiological modality for
brain tumor imaging. MRI provides better contrast resolution
than CT, with better tissue characterization. It can also detect
blood vessels, vascular malformations, and demyelinating
disease (39). It does not involve X-rays or the use of ionizing
radiopharmaceuticals, either. Therefore, MRI is particularly
suitable to image gliomas. Yet, MRI may be perceived as less
comfortable by patients (e.g., overweight or fear of enclosed
spaces) and cannot be performed if the patient has
ferromagnetic implants. In addition, MRI does not show
ossiﬁed or calciﬁed structures as well as CT (such as the
calvarium) and therefore may not show the effects of tumors
on the calvarium in comparison to CT (39, 40).
For GBM MRI, T1-weighted (T1), T1-contrast-enhanced
(T1c or T1-ce), T2-weighted (T2), and ﬂuid-attenuated
inversion recovery (FLAIR) are the most commonly used MRI
s equenc es, be cause t hey can provide differe nt ye t
complementary information in characterizing tissue such as
gray matter, white matter, fat, blood, ﬂuid, and lesions (41,
42). MRI is based on radiofrequency pulses within a magnetic
ﬁeld in which time of repetition (TR) and time of echo (TE) are
calculated. T1 and T1-ce are produced through short TR and TE
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training outcomes for various GBM classiﬁcation applications
(59). Shinohara et al. (60) introduced a set of seven statistical
principles of image normalization (SPIN). In addition to the
common mean-maximum (or standard deviation)
normalizations (59) and histogram-based normalizations (57,
61, 62), Shinohara et al. (60) also proposed a hybrid multimodal
normalization method to match the natural balance of tissue
intensities with physical interpretation. On the other hand, some
data may be standardized (e.g., voxel sizes, resolution) while
others may not. Then, the images are labeled and annotated into
various categories of tissues and/or lesions by experienced
radiologists using a variety of software (e.g., ITK-SNAP (63),
3D Slicer (64)) to produce a labeled/annotated imaging data
set (17).

times; T2 is produced by larger TR and TE times; and FLAIR is
produced through very large TR and TE times. In addition,
diffusion-weighted imaging (DWI) can detect the restriction of
random movements of water molecules that makes DWI
extremely sensitive to detect acute stroke and increased
cellularity as in GBMs, lymphoma, and metastases (43);
magnetic resonance angiography (MRA) and venography
(MRV) can generate pictures of the arteries and veins to
evaluate for stenosis or aneurysms; magnetic resonance
spectroscopy (MRS) is used to measure the levels of different
metabolites and biochemical changes in the brain (44),
providing information on tumor metabolism (45, 46);
perfusion-weighted imaging (PWI) shows the perfusion of
tissues by blood, such as the cerebral blood volume of a tumor
relative to normal-appearing white matter of the brain (47); and
functional MRI (fMRI) detects the increase in blood oxygen level
when blood ﬂow increases to a brain area involved in the
performance of an assigned task (e.g., ﬁnger tapping, lip
pursing, thinking of words, thinking of answers to questions
after hearing a story) (48) and depicts where eloquent brain
areas are in relation to the tumor as the surgeon or radiation
oncologist plans a surgical approach to biopsy or resection or
radiation therapy. The novel amide proton transfer (APT)
imaging can detect amide protons of endogenous mobile
proteins and peptides in tissue based on chemical exchange–
dependent saturation transfer (CEST) MRI (49, 50).
Another useful radiological technology is the PET scan,
which takes advantage of a slightly radioactive substance (e.g.,
C-11 methionine (MET), F-18 ﬂuorothymidine (FLT), F-18
ﬂuoroethyl-L-tyrosine (FET)) that functionally is preferentially
taken up by tumor cells (51). PET is especially helpful for fastgrowing (high-grade) tumors and for distinguishing between
tumors and non-tumor (e.g., scar, inﬂammation) tissue (52, 53).
Therefore, the combined use of MRI and PET can provide
complementary information to achieve more accurate brain
tumor diagnosis (54).

Major public datasets
Since not all ML researchers can directly access private/
customized high-quality labeled/annotated brain tumor datasets,
which are usually owned and protected by medical institutions,
public datasets are essential and provide an equal platform to
these researchers to train and compare the outcomes of their ML
models. In neuro-oncology, one of the most commonly used
public online image datasets is from the Brain Tumor
Segmentation (BraTS) challenges, organized by the Medical
Image Computing and Computer Assisted Interventions
(MICCAI) and other professional organizations (34, 65–69)
since 2012. As of March 2022, the latest BraTS 2021 consists
of a total of 2,040 brain tumor cases/patients, and it is divided
into three subsets: training (1,251 cases), validation (219 cases),
and testing (570 cases). Only training and validation subsets are
open to the public research access, and these two subsets include
a set of multimodal 3D MRI scans (i.e., T1, T1c, T2, FLAIR) for
each case. The training dataset also includes a 3D annotation
model (i.e., GD-enhancing tumor, peritumoral edema/nonenhancing inﬁltrative tumor, necrotic tumor core (NCR), and
normal) for each case (17). In addition, BraTS 2021 includes O6methylguanine-DNA-methyltransferase (MGMT) biomarkers
for 585 patients (out of a total of 1,251 cases) for the training
datasets. It should be noted that, unlike BraTS 2020, BraTS 2021
does not include survival information any longer. BraTS 2020
included the survival information for 265 patients (out of a total
of 460 cases) in the training and validation datasets. Other
widely used datasets include The Cancer Imaging Archive
(TCIA) (70) and The Whole Brain Atlas by Harvard Medical
School (71). TCIA has a collection of 13 brain tumor subdatasets, including the Ivy Glioblastoma Atlas Project (IvyGAP)
(72), The Cancer Genome Atlas (TCGA)-GBM (73), GLIS-RT
(74), and CPTAC-GBM (75). These sub-datasets mainly focus
on high-grade glioma (HGG/GBM) and lower-grade glioma
(LGG). Some of the data in TCIA are also included and
standardized in the most recent BraTS 2021 dataset. The

Radiological image acquisition pipeline
The image acquisition pipelines remain very similar between
radiological scanners (50, 55). Subjects undergoing MRI (i.e.,
patients and control subjects) are usually examined on a clinical
1.5T or 3T scanner with a multichannel receive-only head coil
array under various scanning parameters (e.g., TR, TE, ﬁeld of
view, matrix/voxel size). A sequence of 2D and 3D radiologic
images (e.g., various MRI, CT, PET) is obtained. These images
are cleaned, normalized, and co-registered (i.e., image
preprocessing, Figure 1A). It is worth noting that different
image intensity normalization schemes may inﬂuence not only
the registration (56) and segmentation process (57, 58) but also
the implicit texture features hidden in the different modal MR
images and thus affect the subsequent feature selection and ML
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gray-level co-occurrence matrix (GLCM) (83), and local binary
pattern (LBP) (41). Yet some of these features might be
correlated in that the total number of effective features can be
further reduced, by employing feature selection algorithms such
as principal component analysis (PCA) (84), least absolute
shrinkage and selection operator (LASSO) (85), linear
discriminant analysis (LDA) (86), t-tests (87), analysis of
variance (88), and information gain based methods (89), or
based on certain evaluation criteria, such as probability of error
(POE) and average correlation coefﬁcient (ACC) (59, 90).
Injecting feature extraction and selection can signiﬁcantly help
to reduce the computational complexity of ML models and
speed up the training process and possibly improve the
accuracy of ML models for brain tumor classiﬁcation and
segmentations (91, 92). Nevertheless, one should note that
such preprocessing should be treated with care so that the ML
model is not overﬁtted to particular features, which could lose
generalizability to a different dataset.

Harvard brain atlas consists of the radiology data (e.g., MRI, CT,
PET) for about 40 subsets of normal brain and various brain
disease states. However, none of the datasets in the TCIA or
Harvard brain atlas are pixel-wisely annotated for the ML
segmentation tasks. In addition, the data format for each
patient in TCIA collection varies in terms of pulse sequences
(e.g., T1, T1c, T2, FLAIR, PWI, DWI) and the resolution (i.e.,
with matrices varying from 128*128 to 896*896), even in the
same sub-dataset (e.g., TCGA-GBM, IvyGAP). A summary of
these datasets is depicted in Table 1.

Data augmentation and preprocessing
for the ML models
Data augmentation is a commonly used technique in ML for
the purpose of promoting the accuracy and generalizability of
the ML algorithms. Data augmentation can be attained by 1)
adding slightly modiﬁed copies and/or 2) creating new synthetic
data from already existing data. The former usually employs
geometric transformation and photometric transformation
including ﬂipping, pixel-level augmentation, cropping,
rotating, noise injection, and random erasing (76, 77), while
the latter may make use of generative adversarial networks
(GANs) (78, 79) to create new synthetic images that resemble
the original dataset. It should be noted that GANs also belong to
ML-based networks that require abundant training data to
generate resembled data. Data augmentation acts as a
regularizer and helps reduce class imbalance and overﬁtting
(76), so as to improve both the accuracy and the generalizability
of the ML outcomes.
Current GBM radiomic studies are often hindered by limited
and unbalanced data samples; therefore, using ML models alone
may not achieve statistically signiﬁcant outcomes (80–82). In
this regard, the preprocessing plays a vital role by enhancing and
extracting some image features, especially the biological/medical
meaningful ones in the regions of interests (ROIs), and/or ﬁlters
out some “useless” image data from the datasets, before
performing the ML training and analysis (18). General data
preprocessing approaches for ML models include feature
extraction and feature selection (18, 81). In GBM radiomic
datasets, MRIs contain various features, such as image texture
(23), local histograms (24), structure tensor eigenvalues (25),

Discussion
We have illustrated various radiomic data sources and data
preparation techniques that are commonly employed in MLbased GBM radiomic analysis. One prominent issue in current
GBM radiomic data preparation lies in the lack of standardized
image acquisition speciﬁcations (e.g., repetition time, echo time,
voxel sizes, image resolutions) between different radiological
equipment and medical institutions (i.e., multicenter multivendor, McMv, datasets), which may 1) bias the image data
(e.g., intensity of pixels, actual voxel size); 2) require additional
image data preparation (e.g., cropping, up/down-sampling) to
train ML models with different datasets; and 3) impede the
development and cross-validation of more general/robust and
accurate ML models for McMv datasets. Although BraTS has
made a huge effort and progress in standardizing radiology data
for over 2,000 GBM patients/cases, it is not yet sufﬁcient for
various GBM analysis applications. The second important issue
is that most existing datasets have limited types of brain tumors
(e.g., GBM/HGG, metastasis, and LGG), while the Harvard Atlas
is limited by the number of subjects/patients. Scarcity of brain
tumor/disease types and lack of data impede the application of
ML to accurately distinguish various brain tumors and diseases.

TABLE 1 List of three major sources for radiomic neuro-oncology public datasets.

Dataset

Radiology data
type

BraTS

3D MRI

2,040 subjects, including both HGG and LGG

240 * 240 * 155

TCIA

2D MRI, CT, axial
slices

13 brain tumor sub-datasets, including IvyGAP (39 subjects), TCGA-GBM (262
subjects), and TCGA-LGG (199 subjects)

Varying from 128*128
to 896*896

Harvard Medical School: The
Whole Brain Atlas

2D MRI, CT, PET,
axial slices

8 subsets for brain tumors, and 30 other subsets for normal brains and other nontumor brain diseases

256 * 256
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histopathological processes. More speciﬁcally, such
applications mainly fall into three categories: 1) distinguish
brain tumor from other non-cancerous pathologies; 2)
distinguish GBM from other brain tumors; and 3) differentiate
between true progression and treatment effect (PsP or radiation
necrosis). We hereby provide an overview of a few of these
classiﬁcation problems in brain tumor diagnosis.

Lastly, most datasets include only MRI data while only a few
datasets consist of other modality radiology data such as CT and
PET. Most of them do not include other biological information
(e.g., survival time, histopathological data, biomarkers) either.
There is also lack of longitudinal radiology data to show disease
evolution for patients receiving various treatments. With more
complementary data and medical/treatment history (including
radiomic data) that help comprehensively describe the brain
tumor/disease status, an improvement in the accuracy of
radiomic analysis and prediction can be expected.

1) Differentiating tumor from non-tumor
One of the most critical radiomic functions in brain tumors
is to distinguish between malignant brain tumor and non-tumor
pathologies, which include tumefactive demyelination, infection,
inﬂammation (e.g., paraneoplastic syndromes and autoimmune
disease), cortical dysplasia, and stroke. However, due to
insufﬁcient data available for ML training of each speciﬁc nontumor type, existing studies mostly classify all data into two
major categories: tumor (e.g., GBM/HGG, metastases, LGG) and
non-tumor (i.e., control/normal and non-cancerous pathologies
such as inﬂammation). Some studies tested their ML models on
their own private data, while others took advantage of public
datasets (e.g., BraTS, TCIA, Harvard brain atlas) or a
combination of private and public data to expand the model’s
generalizability. As discussed in Section 2.4, data preprocessing
(e.g., ﬁltering and feature extractions) are also often used to
denoise and enhance the lesion region in the input MRI slides,
with a hope to speed up the ML training process and improve
the accuracy of distinguishing between tumors and non-tumors.
For those using public datasets, Ari et al. (97) proposed a
three-phase extreme learning machine local receptive ﬁeld
(ELM-LRF) method for tumor classiﬁcations: removal of the
noise using local and non-local methods, segmentation of benign
or malignant tumor using ELM-LRF, and then use of a CNN
classiﬁcation. As a result, they achieved an effective classiﬁcation
accuracy of 0.97. Mohsen et al. (84) took advantage of a discrete
wavelet transform (DWT) for feature extraction and principal
component analysis (PCA) for reduction, together with a fuzzy
C-means DNN to classify a dataset of 66 brain MRIs from
Harvard Brain Atlas into four classes, i.e., normal, glioblastoma,
brain sarcoma, and brain metastatic bronchogenic carcinoma
tumors. An accuracy of 0.97 was achieved, and an area under the
curve (AUC) approximated 0.984.
Alves et al. (83) quantiﬁed the gray-level pattern, pixel
interrelationships, and the spectral properties of an image and
achieved two fundamental features from an MRI sample, i.e.,
GLCM and gray-level run-length (GLRL). By combining this
texture analysis with ML models (e.g., SVM, RF), they
differentiated brain tumors from inﬂammatory lesions in their
local MRI dataset and achieved a high accuracy of 0.83 and AUC
of 0.906. Citak-Er et al. (93) applied a multiregional and
multiparametric recursive feature elimination method, which
was based on the Mann–Whitney ranking score, and then they
employed the SVM-based multilayer perceptron (MLP)

Application of AI/ML in
GBM diagnosis and
therapeutic monitoring
The early brain tumor radiomic studies often relied on
conventional radiomic feature-based ML methods that extract
relatively explicit image texture features (e.g., shape, GLCM,
LBP) to train traditional ML models such as SVMs (20–22) and
RFs (23–26) in order to differentiate brain tumor versus nontumors (or different types of brain tumors), predictions of
overall survival, etc. Recently, by taking advantage of deep
neural networks (DNNs) that include more neurons and layers
to statistically recognize global, deep, and implicit imaging
features, DL techniques can achieve state-of-the-art
performance for automatic analysis of brain tumors on
multimodality imaging and clinical data (32). Additionally,
deep feature-based ML techniques build statistically/
biologically meaningful models or utilize DNNs to extract
deep implicit features from the radiology images and then
apply traditional ML models for classiﬁcations (93, 94).
Despite their differences, the above ML models all exploit
prior biomedical and image features knowledge to 1)
preprocess the radiological imaging data to extract imaging
and/or biological meaningful features and 2) optimize the ML
structure/algorithm for speciﬁc classiﬁcation/segmentation
tasks. Examples include the stacked denoising autoencoders
(95) and the Convolutional Restricted Boltzman Machine (96).
All these ML models have been applied in radiomic analysis to
address unmet needs in GBM diagnosis, therapeutic monitoring,
and/or prognosis (e.g., brain tumor classiﬁcations, survival
predictions and biomarker identiﬁcations), while at this point,
CNN-based DL enjoys the most generalizability and highest
accuracy. Details are further discussed under the context of
individual study case as follows.

GBM diagnosis and classiﬁcation
One of the major ML applications in GBM radiomic analysis
is to facilitate the differentiation between GBM and other
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compared 30 diagnostic models that were built based on ﬁve
feature selection models and six classiﬁcation algorithms for
distinguishing GBM and metastases. The ﬁve feature selection
models included distance correlation, RF, least absolute
shrinkage and selection operator (LASSO), eXtreme gradient
boosting (XGBoost), and gradient boosting decision tree
(GBDT), while the six classiﬁcation algorithms included LDA,
SVM, RF, k-NN, Gaussian naïve bayes (GaussianNB), and
logistic regression (LR). The results showed that the
combinational model of distance correlation and LR
outperformed all other combinations in terms of testing
accuracy (0.79) and AUC (0.80), although some other
combinations achieved similar results as well.
Priya et al. (106) analyzed 60 GBM and 60 metastases cases
with 12 regression or ML-based classiﬁer models and four
feature reduction/selection strategies—45 combinations in
total. According to their results, the mean performance of
various models was slightly better with FLAIR images than
multiparametric sequences in terms of AUC, while the
combination of full feature and LASSO achieved the highest
AUC of 0.953, although full features with other models, such as
ElasticNet (107) and RF, achieved similar results. de Causans
et al. (55) trained on T1 MRI data with 71 GBM and 72
metastasis cases using 100 extracted features, based on the
Image Biomarker Standardization Initiative (IBSI) (108). With
these selected features, a total of 144 models combining nine
feature scaling methods and 16 classiﬁers (regression and MLbased) were compared. All 144 classiﬁers of the 21 GBM and 16
metastases cases achieved a mean accuracy and AUC of 0.8 and
0.85, respectively.

classiﬁcation model to achieve a tumor detection accuracy
of 0.93.
Amin et al. (41) mixed the public datasets and local datasets
to differentiate tumors and non-tumors. They employed a
Weiner ﬁlter to denoise and enhance the lesion region in the
input MRI slides and used potential ﬁeld (PF) clustering to
identify the tumor region. Gabor wavelet transform (GWT) and
LBP features were fused with various ML models (i.e., SVM, DT,
k-NN, and naïve Bayes) to further improve the classiﬁcation
accuracy. The approach yielded an accuracy greater than 0.93
and an AUC of 0.96. Zhou et al. (98) treated holistic 3D MRI
samples as sequences of 2D slices to extract some 3D features on
brain tumors. They introduced a recursive structure, i.e., the long
short-term memory (LSTM), to a deep CNN model (i.e.,
DenseNet) to handle such sequential data classiﬁcation, and
this DenseNet-LSTM model achieved an outstanding accuracy
of 0.92 using the BraTS dataset (99).
Both Banerjee et al. (100) and Xu et al. (101) introduced
transfer learning (TL) to improve the accuracy of the DNNbased ML classiﬁer with non-brain-tumor images. They ﬁrst
pretrained the ML classiﬁer with the large general image dataset,
ImageNet (102), and then they ﬁxed the pretrained parameters
in the CNN hidden layers and ﬁne-tuned the parameters in the
output layers with neuro-oncology MRI images. Xu et al. (101)
even embedded an SVM with the CNN to distinguish between
GBM and LGG. By doing so, the two studies achieved
classiﬁcation accuracies of 0.97 and 0.975, respectively.

2) Differentiating primary from secondary
brain tumors
Secondary/metastatic brain tumors have as high as ﬁvefold
incidence of that of primary brain tumors and manifest a rapid
growth, causing signiﬁcant brain tissue damages. Patients
typically present with multiple metastatic tumors throughout
the brain (103). A traditional non-ML-based approach to
distinguish multifocal GBM from metastases on a[ 11 C]methyl-L-tryptophan (AMT)-PET images is to examine the
tumoral standardized uptake values (SUVs), mean tumor/
cortex SUV ratio, and tumor/cortex volume of distribution
(VD)-ratio (104). Compared to GBM, metastases had lower
values of all three parameters. However, this approach can only
achieve an accuracy of 0.72.
Many studies implemented a combination of various feature
extractions and regular ML models to ﬁnd the best performance
for their applications. Zacharaki et al. (86) introduced a Gabor
texture ﬁlter with feature ranking to extract tumor features, and
derived feature ranking scores, and then applied three ML
models to distinguish GBM from metastases: SVM with
recursive feature elimination (SVM-RFE), linear discriminant
analysis (LDA, also known as Fisher linear discriminant) with
Fisher’s discriminant rule (105), and k-NN. Among the three
models, SVM-RFE achieved the highest mean accuracy and
AUC of 0.91 and 0.936, respectively. Chen et al. (85)
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3) Differentiating GBM from primary central
nervous system lymphoma
GBM and primary central nervous system lymphoma
(PCNSL) are not only common intracranial malignancies but
also often share similarities in radiological appearance. However,
the management for each disease is quite different (109).
Recently, multiple ML-based predictive analytics have arisen to
help differentiate GBM from PCNSL radiologically with a
relatively high sensitivity and speciﬁcity. Outcomes were
assessed based on test characteristics such as accuracy,
sensitivity, speciﬁcity, and AUC.
Due to the binary classiﬁcation nature of distinguishing
between GBM and PCNSL, SVM used to be the most
commonly employed model for its computational simplicity
(110–115). Other commonly used ML models such as k-NN
and RF were also exploited and compared (114, 116). Even
though the training datasets were relatively small, approximately
110 or fewer samples with about two-thirds of the entire dataset
containing GBM and one-third of PCNSL, it turned out that
most ML-based models were able to achieve an accuracy
between 0.9 and 0.96, a sensitivity of 0.84 or higher, a
speciﬁcity of 0.89 or higher, and AUC of 0.92 or higher. More
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immune checkpoint inhibitors, such that, per immunotherapy
response assessment in neuro-oncology (iRANO), the patient is
followed for 3 months and then a determination is made of
whether the initial increase in size of the lesion represented
treatment effects or a viable tumor (123–125).
Booth et al. (126) ﬁrst analyzed the tumor heterogeneity in
T2 MRI using topological descriptors called Minkowski
functionals (MFs). Then they utilized an SVM model, together
with image features such as MFs, size, and signal intensity, to
distinguish between pseudoprogression and true progression,
and achieved an accuracy of 0.88, slightly higher than using RF
for feature selection and LASSO for classiﬁcation (0.86). Hu et al.
(127) took advantage of T1 MRI and other eight-dimensional
feature vectors, including T2, FLAIR, proton density, ADC,
PWI, derived relative cerebral blood volume (rCBV), relative
cerebral blood ﬂow (rCBF), and mean transit time maps, to train
an SVM model, and achieved an AUC of 0.94 in distinguishing
between pseudoprogression and true progression. The ADC
map derived from DWI and rCBV and rCBF derived from
PWI were found to make a greater contribution to the
discrimination than the conventional radiology images do.
Due to the time correlation embedded in true progression
and PsP radiology data, Lee et al. (128) and Jang et al. (129)
exploited recursive LSTM-CNN structures on MRI to
distinguish between the two occurrences. In comparison to
Lee’s multimodal MRI data (i.e., T1, T2, FLAIR), Jang et al.
(129) combined/fused T1 MRI data with clinical features to
develop an LSTM-CNN clinic-feature-fused model and achieved
an AUC of 0.87 and F1 score of 0.74, outperforming the model
trained with MRI data only and the RF-based model.
Akbari et al. (130) employed TL with a CNN pretrained on
ImageNet and feature extraction based on four structural MRIs
(i.e., T1, T1-ce, T2, FLAIR), diffusion tensor imaging (DTI), and
PWI (rCBV, peak height (PH), percentage signal recovery
(PSR)) and achieved an accuracy of 0.84 and AUC of 0.83.
Ismail et al. (131) extracted 30 global and local shape features
from T1-ce, T2, and FLAIR images and used an SVM classiﬁer to
achieve an accuracy of 0.90 in distinguishing PsP from true
tumor progression.
In addition to the ambiguity between PsP and true tumor
progression, immunotherapies in GBM also suffer from the lack of
reliable evaluation methods on the radiological imaging
manifestation regarding the alteration of the tumor immune
microenvironment (TME, e.g., tumor immune cell inﬁltration,
functional characterization of immune effector/suppressive cells,
gene expression proﬁle of immunostimulatory/immunosuppressive
cells), a crucial parameter for assessment of intratumoral immune
responses (5). In their pioneering work (132), Narang et al. utilized
T1-weighted post-contrast and T2-FLAIR images in combination
with T-cell surface marker CD3D/E/G mRNA expression data from
78 GBM patient-derived TCGA data to extract six imaging features
that are associated with intra-GBM CD3 activity. These imaging
features were further trained and tested using an internal dataset

notably, Kang et al. (114) and Suh et al. (116) even compared the
prediction outcomes of their ML models with the prediction
from human radiologists, and the results showed the superiority
of ML models over human radiologists in all four criteria,
especially in accuracy, sensitivity, and AUC. It is unknown
whether the combination of the ML model and human
radiologist read would have attained even higher accuracy,
sensitivity, and AUC.
Recently, more sophisticated DL models have been
employed. Priya et al. (117) examined ﬁve different ML
approaches (i.e., LASSO, SVM, RF, Ridge, and MLP) to
distinguish between 97 GBM and 46 PCNSL cases, with all
ﬁve approaches sharing similar results. Yet, LASSO had the best
performance (0.88 in accuracy and 0.92 in AUC) when using
features from the whole tumor, while MLP had the best
performance (0.86 in accuracy and 0.91 in AUC) when only
using the features from the single largest slice. For an even larger
dataset (i.e., 160 GBM and 160 PCNSL), McAvoy et al. (118)
applied a CNN variant, EfﬁcientNet (119), and by using TL
based on ImageNet, they achieved an accuracy of 0.93 and AUC
of 0.94.

4) Differentiating treatment effects versus true
disease progression
Pseudoprogression (PsP) is the apparent growth of a lesion
or development of new lesions on imaging that represents
inﬂammatory treatment-related changes but looks just like
viable tumor growth on MRI. PsP is most common between 3
and 6 months after the completion of radiation therapy, and the
corresponding imaging ﬁndings will subside on their own over
time (120). PsP is more likely in MGMT promoter-methylated
tumors treated with temozolomide. The increased contrast
enhancement on MRI may be caused by the increased vascular
permeability from cytotoxic therapies including radiotherapy
and chemotherapies such as temozolomide, which may beneﬁt
patients receiving immunotherapy and temozolomide but often
leads to premature discontinuation of treatment owing to the
false judgment of progression of disease (121). Radiation
necrosis is another treatment effect that can occur any time
after radiation therapy but is most common 1–2 years after
radiation. It should be differentiated from true progression of
viable tumor before treatment changes are contemplated. As a
result, accurate differentiation between treatment effect (i.e.,
pseudoprogression or radiation necrosis) and true tumor
progression is critical in the treatment decision. PsP may be
associated with a survival advantage. A key radiology tool in
differentiating pseudoprogression or radiation necrosis from
true progression of disease is dynamic susceptibility contrast
(DSC) MR perfusion-weighted imaging (PWI). Elevated
corrected relative cerebral blood volume (crCBV) relative to
normal-appearing white matter is more common in a viable
tumor than in treatment effects (122). However, PWI is
unreliable in patients treated with immunotherapy such as
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patient survival and molecular subtype. The predictors were
evaluated in 29 new patients and achieved a three-way (long/
medium/short survival for longer than 18 months, between 6
and 18 months, and shorter than 6 months) accuracy of about
0.80. Another classiﬁer was trained to discriminate among each
of the various GBM molecular subtypes and achieved an
accuracy of about 0.76. Sanghazni et al. (136) derived texture
features (e.g., ﬁrst-order texture features, GLCM), tumor shape
and volumetric features, and patient ages from 173 patients’
multimodal MRI data (e.g., T1-ce, T2, and Flair) and used an
SVM-RFE-based ML model to perform binary (i.e., short and
long‘s threshold upon 400 days) and multiclass (i.e., <10, 10~15,
and >15 months) OS prediction. Prediction accuracies of 0.987
and 0.89 were achieved for binary and multiclass
predictions, respectively.
Choi et al. (137) collected 250 radiomic features extracted
from 296 LGG cases from institutional and TCGA/TCIA
datasets. They trained three random survival forest (RSF, i.e., a
variant of RF) models with 1) these radiomic features; 2) nonimaging prognostic factors including age, resection extent,
WHO grade, and IDH status; and 3) combination of 1 and 2
on the institutional dataset and validation of the model on the
TCGA/TCIA dataset. When applying radiomic features or nonimaging features alone, the two RSF models achieved an AUC of
0.620 and 0.627, respectively. When applying radiomic features
together with non-imaging prognostic parameters, the AUC was
improved to 0.709. Similarly, in a GBM hypoxia-associated
radiomic study, Beig et al. (138) also revealed that when
combining clinical features (age, gender, and Karnofsky
Performance Score (KPS)) with 270 radiomic features, the
concordance index for survival prediction rises to 0.83 in
comparison to 0.74 when using radiomic features alone (138).
Grist et al. (139) examined various analysis techniques on
survival predictions through perfusion and MRI data,
especially DWI, collected from 69 pediatric patients.
Approaches included conventional regressions and Bayesian
analysis on apparent diffusion coefﬁcient (ADC) maps,
uncorrected and corrected cerebral blood volume (uCBV and
cCBV) maps, and K2 maps (140) and achieved an AUC between
0.63 and 0.82. Supervised (i.e., SVM, RF, and a single-layer
neural network) and unsupervised (i.e., k-means clustering) ML
analyses achieved an accuracy between 0.90 and 0.98 in
distinguishing between high- and low-risk clusters, with
distinct differences in survival. In addition to the above
models, the Tiwari group has developed a radiomic risk score
in which the extracted GBM radiomic features were trained by
various Cox regression-based algorithms for survival
stratiﬁcation with an overall concordance index at 0.7 to 0.8
(141–143).
Nie et al. (134) proposed a two-stage learning-based method
to predict the OS of HGG patients. Speciﬁcally, in the ﬁrst stage,
they adopted a CNN to extract implicit features from
multiparametric maps that are computed by multimodal

from 69 GBM patients that has immunohistochemically (IHC)
validated intratumoral CD3 counts. The image-based intra-GBM
CD3+ T-cell inﬁltration model reaches an accuracy of 97.1% and
AUC of 0.993 for the training set, with an accuracy of 76.5% and
AUC of 0.847 in the test group. A similar study has been reported
recently in lower-grade gliomas (LGG) with an expansion from
CD3 expression data to multiple immune gene expression proﬁles,
including major histocompatibility complex (MHC)-related
molecules, immune checkpoint molecules, and effector/suppressor
immune cells (94). In this study, radiomic features extracted by a
deep learning neural network-based model have been demonstrated
to predict the TME-associated signature immunophenotype
mRNAs with an AUC of 0.821 in the test group. Unfortunately,
there is no IHC validation on expression of signature immune genes
in the test group specimens.
To date, although numerous ML models for differentiating
PsP from true tumor progression have been proposed and tested,
none of them have been prospectively validated, reﬂecting the
lack of conﬁdence in clinicians to apply these radiomic
approaches in their clinic practice. Multiple factors can lead to
this signiﬁcant issue, such as difﬁculty to applying small sample
size-derived prediction models to a large population cohort,
poor reproducibility, and lack of consistency between various
ML models and/or datasets (further discussed in Section 4). One
of the important and challenging factors is that currently there is
no clear objective histological deﬁnition of pseudoprogression.
In a representative study by Melguizo-Gavilanes et al. (133),
MRI images and surgical resection-derived histological data
from 34 patients with GBM were retrospectively reviewed.
Only one-third of the cohort (11/34) demonstrated a
concordance for PsP between radiological interpretation and
histological diagnosis, whereas the majority of the patients had a
histologically “mixed” pattern with tumor and treatment effect,
indicating that even histology might not be applied as a gold
standard to differentiate PsP and tumor true progression.

Overall survival prediction
Overall survival prediction of GBM patients provides useful
information for surgical and treatment planning. Conventional
survival prediction based on clinical information is subjective
and could be inaccurate. Radiomic analysis, on the other hand,
provides a variety of MRI features to predict disease prognosis,
thus providing beneﬁcial information for personalized
treatment. Nevertheless, manual feature engineering is still
time consuming, laborious, and subjective and may not be
able to effectively encode other predictive but implicit
information hidden in the multimodal neuroimages (134).
Thus, an accurate, generalized yet automated OS prediction
is desired.
Macyszyn et al. (135) extracted about 60 features from 105
GBM patients to train an SVM-based predictive model for
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MGMT promoter methylation

multichannel MRI (i.e., T1-ce, DTI, and rs-fMRI) from 68 HGG
patients. Then, those radiomic features along with the
demographic and tumor-related features (e.g., age, tumor size,
and histological type) were trained in an SVM to model OS
prediction (i.e., long or short overall survival time, with a
threshold of 650 days). The experimental results demonstrated
an accuracy of up to 0.91.

MGMT promoter methylation predicts less aggressive
glioma behavior for both IDH-mutated and IDH-wild-type
gliomas. When its promoter is methylated, the MGMT gene,
which is involved in DNA repair, is hindered and the tumor has
greater difﬁculty overcoming the damage caused by
chemotherapy such as temozolomide. Yogananda et al. (146)
used a 3D-dense UNet on only T2 images to simultaneously
segment the tumor and predict the presence of MGMT promoter
methylation with a mean three-fold cross-validation accuracy of
0.95 (sensitivity 0.96, speciﬁcity 0.92, AUC 0.93, Dice
score 0.82).

Identifying biomarkers of brain tumors
Radiogenomics uses radiomics techniques to predict the
genetic makeup of tumors. This promotes precision medicine
by identifying patients with tumor molecular markers that can
be targeted by particular drugs and by predicting how aggressive
a tumor will behave, with implications for survival and treatment
choice. Via exploring the implicit correlation between
radiological images and genomic data such as DNA
microarrays, microRNA, RNA-Seq, ML techniques can help
improve the effectiveness and efﬁciency in identifying the
biomarkers of brain tumors (144).

H3K27M alterations
In 2016, the WHO released a new histological diagnosis in the
classiﬁcation of CNS malignancies: diffuse midline glioma
(DMG), H3K27M-mutant. It was renamed as H3K27M-altered
in 2021 because there are multiple mechanisms involved. These
WHO grade 4 tumors are found in or near the midline in the
brainstem, thalamus, spinal cord, pineal region, hypothalamus,
and cerebellum and exhibit aggressive clinical behavior (147, 148).
H3K27M is the most frequent mutation in brainstem gliomas
(BSGs) (149). Su et al. (150) extracted radiomics features from
FLAIR images from 40 patients with H3K27M mutations and 60
wild-type patients, all with midline gliomas. The Tree-based
Pipeline Optimization Tool (TPOT) was applied to optimize the
ML pipeline and select important radiomics features. A total of 10
independent TPOT ML models were compared and tested on 22
independent cohorts of patients, achieving an accuracy ranging
from 0.6 to 0.84, and the AUC from 0.73 to 0.90. Pan et al. (149)
included a total of 151 patients with newly diagnosed BSGs. A
total of 1,697 features, including six clinical parameters and 1,691
imaging features (e.g., GLCM, LBP), were extracted from pre- and
post-contrast T1 and T2 images. Spearman’s correlation and relief
algorithm were applied for feature selection. Thirty-six MRI
features and three clinical features remained and were fed to an
RF model to predict H3K27M mutations. For comparison, a leastsquare estimation method-based ML model was developed by
utilization of the KPS at diagnosis, symptom duration at diagnosis,
and edge sharpness on T2, which achieved an accuracy of 0.80 and
AUC of 0.79 in the test cohort if using MRI features alone but can
be improved to 0.84 and an AUC of 0.83 if integrated with clinical
parameters. The simpliﬁed model achieved an AUC of 0.78. Zhuo
et al. (151) studied 81 BSG patients with APT imaging at 3T MR
and known H3K27M status. APTw values (i.e., mean, median, and
max) and radiomic features within manually delineated 3D tumor
masks were extracted. H3K27M-mutant prediction using APTwderived radiomics was conducted using various models, such as
SVM, AdaBoost, autoencoder, LASSO regression, and RF, which
achieved an accuracy of 0.86 and an AUC of 0.93 as validated by a
prospective cohort of 29 BSG patients.

Isocitrate dehydrogenase (IDH) mutation
Since the initial reworking of the WHO CNS Tumor
Classiﬁcation System in 2016, genetic biomarkers have become
increasingly important in the classiﬁcation of brain tumors.
Isocitrate dehydrogenase is an enzyme in the Krebs cycle, and
its mutated gene (IDH) is an oncogene. The mutant IDH enzyme
produces an oncometabolite 2-hydroxyglutarate (2HG) (145),
which promotes the growth of various cancers throughout the
body. In brain tumors, IDH-mutated tumors are less aggressive
than IDH wild-type tumors, yet they can convert to the latter. In
the 2021 WHO CNS Tumor Classiﬁcation System, only IDH wildtype tumors are classiﬁed as GBMs. It is of utmost importance for
therapeutic planning to differentiate between the IDH mutation
and IDH wild type, and it would greatly beneﬁt patients if this
determination could be done non-invasively and obviate biopsy or
resection. Yogananda et al. (33) developed a 3D Dense-UNet
network using (a) T2 images only (T2-net) and (b) a combination
of T1-ce, T2, and FLAIR images (TS-net) from TCIA and TCGA
to non-invasively predict IDH mutation. The T2-net
demonstrated a mean cross-validation accuracy of 0.97
(sensitivity 0.97, speciﬁcity 0.98, AUC 0.98), and TS-net
demonstrated a mean cross-validation accuracy of 0.97
(sensitivity 0.98, speciﬁcity 0.97, AUC 0.99). In addition, this
model automatically segmented the tumor to show areas with
either IDH mutation or IDH wild type. Dice scores were 0.85 for
T2-net and 0.89 for TS-net. The beneﬁt of being able to use only
T2-weighted images is that gadolinium-based contrast material,
which deposits in the brain to unknown effect, does not have to be
administered and T2-weighted images can be quickly acquired
and are less sensitive to motion artifact.
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not be a “deterministic optimal” algorithm or architecture for an
ML model to achieve the “ideal/optimal” outcomes. The initial
values of the trainable parameters in ML models and the slight
differences in structure may affect the training outcome
signiﬁcantly. Even when using public datasets (e.g., BraTS),
similar ML networks may yet achieve varying results (152,
153). Thus, many researchers intend to simply add more
layers in CNNs to improve the accuracy, potentially causing
extensive yet unnecessary computational complexity during the
training process but overlooking the biological connections and
meaning behind those data. On the other hand, too much
engineering (i.e., strong feature extraction, data restriction/
collection) in data preprocessing may also lead to overﬁtting
of the ML network to the training data and lose the
generalizability of trained ML models for larger populations
with more diversity (Figure 1B).

Discussion
Despite that numerous ML studies have been conducted in
GBM radiomic analysis, comparing the results from individual
articles is not a trivial task due to the use of different data sets.
The accuracies, AUCs, and Dice scores in different studies may
vary from 0.7 to 0.98: most state-of-the-art studies using public
datasets (e.g., BraTS) achieve an accuracy of 0.84–0.94, but some
studies with certain private data can reach 0.98. Meanwhile,
current major public datasets also lack sub-categories for brain
tumor classiﬁcation and segmentations, which restricts the
development of a more powerful and comprehensive MLmodel to distinguish more brain tumor types. Without
sufﬁciently large datasets, ML models with too many
parameters (i.e., neurons in each layer and the number of
layers) are easily overﬁtting to a speciﬁc dataset, losing the
generalizability of the model to other patient groups.

Promising strategies enhancing
performance of AI models in GBM
radiomic analysis

Challenges and perspectives on
future AI/ML techniques
Overview of current challenges in MLbased radiomic neuro-oncology studies

Aside from using genuine radiological brain tumor images
alone to train ML models, three other trends are gaining
popularity to improve the model performance in accuracy,
Dice score, AUC, and generalizability. The ﬁrst trend is to use
TL (100, 101), which takes advantage of other larger non-neurooncology or even non-medical image datasets to pretrain the ML
model. Then by keeping the pretrained parameters in the lowlevel hidden layers (i.e., closer to the input layer) and ﬁne-tuning
the ones in the high-level layers and output layers with brain
tumor training image datasets, the pretrained ML model can be
adopted for brain tumor analysis. Typical image datasets for
pretraining ML models includes ImageNet (102), the modiﬁed
National Institute of Standards and Technology (MNIST)
database (154), and International Symposium on Biomedical
Imaging (ISBI) (155). However, if the pretraining dataset is
drastically unsimilar to the target dataset, the pretraining effect is
limited. Therefore, a standardized radiomic medical dataset with
various categories is preferred, beneﬁtting not only neurooncology studies but also other medical and biomedical studies.
The second trend is to use GANs to generate synthetic data
for augmentation (78, 79, 155). However, as discussed in Section
2.4, this approach itself requires a large set of genuine images to
train the discriminator network in the GAN, before it can
synthesize accurate-appearing brain tumor images to train
other ML models for brain tumor analysis.
The third trend is to fuse multimodal data for a more
comprehensive analysis. Examples include multimodal MRI
(156, 157), combinations of MRI and PET (54), image
genomics (i.e., radiogenomics), and clinical data to study the
association between imaging biomarkers and genomic

As ML is a data-driven statistical approach to extract common
features within different data samples, sufﬁcient imaging datasets
are required to train advanced ML models and to fairly evaluate
their performances (e.g., accuracy, Dice score, AUC) in the ﬁeld of
neuro-oncology. Currently, only a limited number of brain tumor
sub-categories have been analyzed with ML studies while many
other brain tumor/disease types have not, due to the lack of labeled/
annotated data for training. Examples include differentiating
dysembryoplastic neuroepithelial tumor (DNET), ganglioglioma,
pleomorphic xanthoastrocytoma (PXA), and multinodular and
vacuolating neuronal tumor (MVNT).
However, establishing standardized radiological imaging
datasets or standardizing McMv datasets for extensive and
generalized ML-based GBM analysis can be manpower and
time consuming because most of these datasets require highly
accurate manual labeling/annotation to serve as the “ground
truth” for the ML model training and validation. In addition,
these datasets should be generalizable for various neurooncology analyses and patient groups and should be carefully
labeled by various disease categories. Additional information
(e.g., survival time, related biotest results, related clinical/
medical history) may also be necessary for more sophisticated
and comprehensive analyses. This requires a continuous update
of the datasets, leading to a signiﬁcant cost of data management
(Figure 1B).
Another challenge is that current mathematic mechanisms
in the ML model are based on statistics, which means there may
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improving dataset quality, employing multimodal data fusion,
developing more advanced ML models, and further enhancing
collaborations between computer scientists, engineers,
physicians, and biomedical researchers, AI techniques will
accelerate quantitative cancer imaging analysis for clinical
applications with great improvements in patient care.

characteristics (144, 149–151, 158, 159). Especially for
radiogenomics, some studies (144, 158, 159) have identiﬁed
associations between quantitative image features and gene
expression proﬁles of glioblastoma (e.g., H3K27M, TP53,
EGFR, NF1, and IDH1) and its molecular subtypes (e.g.,
classical, mesenchymal, proneural, and neural). Additional
studies indicate that quantitative MR imaging features derived
from entire tumor volumes can be used to identify glioblastoma
subtypes with distinct molecular pathways (160, 161). With the
help of additional complementary correlated features from
different types of radiomic images and/or genomic
information, or simply just the medical history of the patients,
ML can take advantage of data to achieve more accurate
predictions (Figure 1B).
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analysis. However, challenges remain for exploring cancer
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